학술논문
Does neoadjuvant chemotherapy regimen affect sarcopenia status in patients with breast cancer?
Document Type
article
Author
Source
Breast, Vol 66, Iss , Pp 1-7 (2022)
Subject
Language
English
ISSN
1532-3080
Abstract
Background: Low muscle mass, or sarcopenia, predicts poorer treatment outcomes in breast cancer. Neoadjuvant chemotherapy is the main treatment to improve surgical outcomes for breast cancer, yet few studies have assessed the relationships between different chemotherapy regimens and sarcopenia. This study compared body composition change between two neoadjuvant chemotherapy regimens: AC-T (anthracyclines and cyclophosphamide followed by a taxane) and TCHP (docetaxel, carboplatin, trastuzumab, and pertuzumab). Methods: This study included 298 patients with breast cancer who received neoadjuvant chemotherapy between 2017 and 2020 at one university hospital. Body composition was assessed by computed tomography. Multiple linear regression was performed to examine predictors of SMI change. Results: Patients receiving TCHP showed a significant mean skeletal muscle index (SMI) decrease of 1.6 cm2/m2 (SD = 3.5, p